Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Optimizing psychedelic compounds for neuropsychiatric therapy

A Correction to this article was published on 05 May 2021

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

References

  1. 1.

    Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;11:611–24.

    Article  Google Scholar 

  2. 2.

    Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619–27.

    Article  Google Scholar 

  3. 3.

    Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020. https://doi.org/10.1021/acsptsci.0c00194.

  4. 4.

    Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589:474–9.

    CAS  Article  Google Scholar 

  5. 5.

    Wasko MJ, Witt-Enderby PA, Surratt CK. DARK classics in chemical neuroscience: Ibogaine. ACS Chem Neurosci. 2018;9:2475–83.

    CAS  Article  Google Scholar 

  6. 6.

    Yan QS, Yan SE. Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol. 2001;418:55–64.

    CAS  Article  Google Scholar 

  7. 7.

    Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylor K, Bailey AM, et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat Neurosci. 2013;16:464–72.

    CAS  Article  Google Scholar 

  8. 8.

    Bale TL, Abel T, Akil H, Carlezon WA Jr, Moghaddam B, Nestler EJ, et al. The critical importance of basic animal research for neuropsychiatric disorders. Neuropsychopharmacology. 2019;44:1349–53.

    Article  Google Scholar 

  9. 9.

    Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.

    CAS  Article  Google Scholar 

  10. 10.

    Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P, et al. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci USA. 2009;106:19575–80.

    CAS  Article  Google Scholar 

  11. 11.

    Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai X et al. An excitatory synapse hypothesis of depression. Trends Neurosci. 2015;38:279–94.

    CAS  Article  Google Scholar 

  13. 13.

    Fischer AS, Holt-Gosselin B, Fleming SL, Hack LM, Ball TM, Schatzberg AF, et al. Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. Neuropsychopharmacology 2021;46:809–19.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Scott M. Thompson.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: The pharmacology of ibogaine was characterized incorrectly.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thompson, S.M. Optimizing psychedelic compounds for neuropsychiatric therapy. Neuropsychopharmacol. (2021). https://doi.org/10.1038/s41386-021-01004-7

Download citation

Search

Quick links